Inhibition of gluconeogenesis at the phosphoenolpyruvate carboxykinase and pyruvate carboxylase reactions, as a means of cancer chemotherapy.
D000818:Animals; D002279:Carcinoma 256, Walker / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D005943:Gluconeogenesis / Q000187:drug effects*; D006367:HeLa Cells / Q000187:drug effects; D006834:Hydrazines / Q000494:pharmacology / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000378:metabolism; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000037:antagonists & inhibitors*; D011766:Pyruvate Carboxylase / Q000037:antagonists & inhibitors*; D051381:Rats; D014364:Tryptophan / Q000494:pharmacology / Q000627:therapeutic use*
D006834:Hydrazines; D014364:Tryptophan; D010729:Phosphoenolpyruvate Carboxykinase (GTP); D011766:Pyruvate Carboxylase